IL213098A - In vitro methods that include sicam measurement to test whether a patient will respond to treatment - Google Patents

In vitro methods that include sicam measurement to test whether a patient will respond to treatment

Info

Publication number
IL213098A
IL213098A IL213098A IL21309811A IL213098A IL 213098 A IL213098 A IL 213098A IL 213098 A IL213098 A IL 213098A IL 21309811 A IL21309811 A IL 21309811A IL 213098 A IL213098 A IL 213098A
Authority
IL
Israel
Prior art keywords
sicam
respond
patient
measuring
treatment
Prior art date
Application number
IL213098A
Other languages
English (en)
Hebrew (he)
Other versions
IL213098A0 (en
Inventor
Bruce Acres
Berangere Marie-Bastien
Original Assignee
Transgene Sa
Bruce Acres
Berangere Marie-Bastien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa, Bruce Acres, Berangere Marie-Bastien filed Critical Transgene Sa
Publication of IL213098A0 publication Critical patent/IL213098A0/en
Publication of IL213098A publication Critical patent/IL213098A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525ICAM molecules, e.g. CD50, CD54, CD102
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL213098A 2009-01-20 2011-05-24 In vitro methods that include sicam measurement to test whether a patient will respond to treatment IL213098A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305044 2009-01-20
EP09305294 2009-04-07
PCT/EP2010/050532 WO2010084100A1 (en) 2009-01-20 2010-01-18 Soluble icam-1 as biomarker for prediction of therapeutic response

Publications (2)

Publication Number Publication Date
IL213098A0 IL213098A0 (en) 2011-07-31
IL213098A true IL213098A (en) 2015-08-31

Family

ID=42028081

Family Applications (1)

Application Number Title Priority Date Filing Date
IL213098A IL213098A (en) 2009-01-20 2011-05-24 In vitro methods that include sicam measurement to test whether a patient will respond to treatment

Country Status (23)

Country Link
US (2) US20110312525A1 (enExample)
EP (1) EP2382474B1 (enExample)
JP (1) JP5379243B2 (enExample)
KR (1) KR20110116016A (enExample)
CN (1) CN102292638B (enExample)
AU (1) AU2010206195B2 (enExample)
BR (1) BRPI1006901A2 (enExample)
CA (1) CA2749192A1 (enExample)
CO (1) CO6390020A2 (enExample)
CR (1) CR20110438A (enExample)
DK (1) DK2382474T3 (enExample)
ES (1) ES2536747T3 (enExample)
HR (1) HRP20150470T1 (enExample)
HU (1) HUE025015T2 (enExample)
IL (1) IL213098A (enExample)
MX (1) MX2011007386A (enExample)
NZ (1) NZ593749A (enExample)
PL (1) PL2382474T3 (enExample)
PT (1) PT2382474E (enExample)
SG (2) SG196837A1 (enExample)
TW (1) TWI440854B (enExample)
WO (1) WO2010084100A1 (enExample)
ZA (1) ZA201105271B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103175959B (zh) * 2013-02-28 2015-10-14 成都创宜生物科技有限公司 一种检测胎膜早破免疫层析试纸的制备方法
CN103235134B (zh) * 2013-05-08 2015-10-14 成都创宜生物科技有限公司 一种检测胎膜早破的免疫层析试纸及其制备方法
CN103698537A (zh) * 2014-01-06 2014-04-02 天津医科大学总医院 定量检测人血清可溶性细胞间粘附分子-1的化学发光免疫分析试剂盒及检测方法
CN112292142A (zh) * 2018-03-06 2021-01-29 Pepvax公司 核酸分子及其使用方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
FR2602790B1 (fr) * 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6054438A (en) 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
EP0289949B1 (en) 1987-05-04 1995-10-04 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
CA2008368C (en) 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
AU672359B2 (en) 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1998004727A1 (en) 1996-07-25 1998-02-05 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
AU727308B2 (en) 1997-02-24 2000-12-07 Dana-Farber Cancer Institute Recombinant pox virus for immunization against muc1 tumor-associated antigen
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
ES2220448T3 (es) 1999-02-04 2004-12-16 Geron Corporation Secuencias reguladoras de la transcripcion de la telomerasa transcriptasa inversa.
ATE332364T1 (de) 1999-02-22 2006-07-15 Transgene Sa Verfahren zur gewinnung von purifizierter virenzuammensetzung
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US7001596B1 (en) 1999-11-15 2006-02-21 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
DE20122302U1 (de) 2000-11-23 2005-02-24 Bavarian Nordic A/S Variante des Modifizierten Vaccinia-Ankara-Virus
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
FR2855758B1 (fr) 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
FR2862648B1 (fr) 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
US7381536B2 (en) 2005-03-01 2008-06-03 Gurbel Paul A Assessment of cardiac health and thrombotic risk in a patient

Also Published As

Publication number Publication date
EP2382474A1 (en) 2011-11-02
EP2382474B1 (en) 2015-03-04
JP5379243B2 (ja) 2013-12-25
ZA201105271B (en) 2012-03-28
TW201031917A (en) 2010-09-01
RU2011134415A (ru) 2013-02-27
SG173065A1 (en) 2011-08-29
CN102292638B (zh) 2014-05-28
IL213098A0 (en) 2011-07-31
PT2382474E (pt) 2015-06-03
MX2011007386A (es) 2011-08-03
HUE025015T2 (en) 2016-04-28
TWI440854B (zh) 2014-06-11
BRPI1006901A2 (pt) 2016-02-16
US20110312525A1 (en) 2011-12-22
HRP20150470T1 (hr) 2015-06-05
KR20110116016A (ko) 2011-10-24
JP2012515893A (ja) 2012-07-12
AU2010206195B2 (en) 2016-03-10
CR20110438A (es) 2011-12-28
NZ593749A (en) 2012-05-25
SG196837A1 (en) 2014-02-13
HK1161643A1 (en) 2012-07-27
ES2536747T3 (es) 2015-05-28
US20140023686A1 (en) 2014-01-23
AU2010206195A1 (en) 2010-07-29
CA2749192A1 (en) 2010-07-29
CN102292638A (zh) 2011-12-21
PL2382474T3 (pl) 2015-08-31
WO2010084100A1 (en) 2010-07-29
DK2382474T3 (en) 2015-04-07
CO6390020A2 (es) 2012-02-29

Similar Documents

Publication Publication Date Title
GB0921477D0 (en) Apparatus for measuring blood parameters
IL253648B (en) The device intended for implantation in a patient's heart
IL222463B (en) A non-invasive method for measuring glucose
AP2013006667A0 (en) A device and methods for in vivo monitoring of an individual
ZA201206207B (en) Device and method for determining information related to a medical device
PL2348972T3 (pl) Urządzenie do pomiaru ciśnienia krwi i sposób pomiaru ciśnienia krwi żywej istoty
PL2477551T3 (pl) Sposób pomiaru co najmniej jednej właściwości tkanki biologicznej
GB0802990D0 (en) Methods of calibrating a sensor in a patient monitoring system
ZA201300996B (en) Non-invasive blood pressure measuring apparatus and measuring method thereof
ZA201202189B (en) Blood collection device
PT2576825T (pt) Métodos para avaliar a receptividade do endométrio de uma doente
GB2488743B (en) Physiological monitoring device and method
EP2451347A4 (en) NON-INVASIVE MEASUREMENT OF A PHYSIOLOGICAL PROCESS
PL2432391T3 (pl) Aparat do pomiaru tętna
IL219894A0 (en) Method and apparatus for measuring spinal characteristics of a patient
IL213098A (en) In vitro methods that include sicam measurement to test whether a patient will respond to treatment
PT2470066E (pt) Método não invasivo para avaliação da perfusão de tecidos num doente
GB201014102D0 (en) Patient compliance monitoring device - pharmaceuticals
IL202172A0 (en) Correct blood pressure measurement system and method
IL218400A0 (en) Compact probe for tracer-assisted diagnostic and surgery
PT2654555T (pt) Braçadeira de medição de pressão arterial
PT2654553T (pt) Braçadeira de medição de pressão arterial
EP2528500A4 (en) METHOD AND DEVICE FOR MEASURING A TISSUE PRINT
HU4178U (en) Medical instrument and method for bronhoscopic examination by jet-connector
PL2322095T3 (pl) Aparat pomiarowy do badania parametrów krwi

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees